<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Atazanavir</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01072</strong>&#160; (APRD00804)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Atazanavir (formerly known as <span class="caps">BMS</span>-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (<span class="caps">HIV</span>). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient&#8217;s lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other <span class="caps">HIV</span> medications. The U.S. Food and Drug Administration (<span class="caps">FDA</span>) approved atazanavir on June 20, 2003. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01072/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01072/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01072.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01072.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01072.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01072.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01072.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01072">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>ATV</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>ATZ</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Atazanavir sulfate</strong>
          <div class="cas">229975-97-7</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000426/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000426/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: DQSGVVGOPRWTKI-QVFAWCHISA-N</li>
              <li>Monoisotopic Mass: 802.35712729</li>
              <li>Average Mass: 802.934</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000426">DBSALT000426</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Latazanavir</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Reyataz</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zrivada</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-hiv-agents">Anti-HIV Agents</a></li>
<li><a href="/mesh/hiv-protease-inhibitors">HIV Protease Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>198904-31-3</td></tr><tr><th>Weight</th><td>Average: 704.8555<br>Monoisotopic: 704.389748048</td></tr><tr><th>Chemical Formula</th><td>C<sub>38</sub>H<sub>52</sub>N<sub>6</sub>O<sub>7</sub></td></tr><tr><th>InChI Key</th><td>AXRYRYVKAWYZBR-GASGPIRDSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">methyl N-[(1S)-1-{N'-[(2S,3S)-2-hydroxy-3-[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethylbutanamido]-4-phenylbutyl]-N'-{[4-(pyridin-2-yl)phenyl]methyl}hydrazinecarbonyl}-2,2-dimethylpropyl]carbamate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC(=O)N[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(CC1=CC=C(C=C1)C1=CC=CC=N1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>N-acyl-alpha Amino Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Alpha Amino Acid Amides; Phenylpyridines; Amphetamines and Derivatives; Dicarboxylic Acids and Derivatives; Secondary Carboxylic Acid Amides; Secondary Alcohols; Carbamic Acids and Derivatives; Carboxylic Acid Hydrazides; Carboxylic Acids; Polyamines; Ethers; Enolates; Hydrazines and Derivatives</td></tr><tr><th>Substituents</th><td>amphetamine or derivative; pyridine; dicarboxylic acid derivative; benzene; carboxamide group; carbamic acid derivative; secondary carboxylic acid amide; secondary alcohol; carboxylic acid hydrazide; enolate; carboxylic acid; ether; polyamine; hydrazine derivative; alcohol; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the n-acyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an acyl group at his terminal nitrogen atom.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.</td></tr><tr><th>Pharmacodynamics</th><td>Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs. Atazanivir is pharmacologically related but structurally different from other protease inhibitors and other currently available antiretrovirals.</td></tr><tr><th>Mechanism of action</th><td>Atazanavir selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells by binding to the active site of HIV-1 protease, thus preventing the formation of mature virions. Atazanavir is not active against HIV-2.</td></tr><tr><th>Absorption</th><td>Atazanavir is rapidly absorbed with a T<sub>max</sub> of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability. Oral bioavailability is 60-68%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>86% bound to human serum proteins (alpha-1-acid glycoprotein and albumin). Protein binding is independent of concentration.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Atazanavir is extensively metabolized in humans, primarily by the liver. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. In vitro studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Elimination half-life in adults (healthy and HIV infected) is approximately 7 hours (following a 400 mg daily dose with a light meal). Elimination half-life in hepatically impaired is 12.1 hours (following a single 400 mg dose).</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.7997</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9409</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7017</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.832</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.81</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.844</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.924</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6463</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7553</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7041</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.848</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5948</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8425</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7718</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6714
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7261
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7082 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9766
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6538
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bristol myers squibb co</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>PCA LLC</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Reyataz 300 mg capsule</td><td>36.63USD</td><td>capsule</td></tr><tr><td>Reyataz 150 mg capsule</td><td>18.49USD</td><td>capsule</td></tr><tr><td>Reyataz 200 mg capsule</td><td>18.49USD</td><td>capsule</td></tr><tr><td>Reyataz 100 mg capsule</td><td>18.12USD</td><td>capsule</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6087383</td><td>1998-12-21</td><td>2018-12-21</td></tr><tr><td>United States</td><td>5849911</td><td>1997-06-20</td><td>2017-06-20</td></tr><tr><td>Canada</td><td>2250840</td><td>2006-07-04</td><td>2017-04-14</td></tr><tr><td>Canada</td><td>2317736</td><td>2004-11-02</td><td>2018-12-22</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>water solubility</td><td>Free base slightly soluble (4-5 mg/mL)</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>4.5</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>3.27e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.08</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.54</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-5.3</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>11.92</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>4.42</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>171.22</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>18</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>191.8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>76.83</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p><a href="http://www.drugsyn.org/Atazanavir.htm">DrugSyn.org</a></p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5849911&amp;tbm=pts" target="_blank">US5849911 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Croom KF, Dhillon S, Keam SJ: Atazanavir: a review of its use in the management of <span class="caps">HIV</span>-1 infection. Drugs. 2009 May 29;69(8):1107-40. doi: 10.2165/00003495-200969080-00009. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19496633">Pubmed</a></li>
	<li>von Hentig N: Atazanavir/ritonavir: a review of its use in <span class="caps">HIV</span> therapy. Drugs Today (Barc). 2008 Feb;44(2):103-32. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18389089">Pubmed</a></li>
	<li>Swainston Harrison T, Scott LJ: Atazanavir: a review of its use in the management of <span class="caps">HIV</span> infection. Drugs. 2005;65(16):2309-36. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16266202">Pubmed</a></li>
	<li>Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44(10):1035-50. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16176117">Pubmed</a></li>
	<li>Lopez-Cortes LF: [Pharmacology, pharmacokinetic features and interactions of atazanavir] Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:2-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20116610">Pubmed</a></li>
	<li>Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15585441">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D01276" target="_blank">D01276 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=148192" target="_blank">148192 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508504" target="_blank">46508504 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.130642.html" target="_blank">130642 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=13934" target="_blank">13934 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=37924" target="_blank">37924 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1163" target="_blank">CHEMBL1163 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DNC000332" target="_blank">DNC000332 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA10251" target="_blank">PA10251 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2248610" target="_blank">2248610 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/reyataz.htm" target="_blank">http://www.rxlist.com/cgi/generic/reyataz.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/atazanavir.html" target="_blank">http://www.drugs.com/cdi/atazanavir.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rey1671.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/rey1671.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Atazanavir" target="_blank">Atazanavir <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>J05AE08<ul class="atc-drug-tree"><li><a href="/atc/J#J">J &#8212; ANTIINFECTIVES FOR SYSTEMIC USE</a></li><li><a href="/atc/J05#J05">J05 &#8212; ANTIVIRALS FOR SYSTEMIC USE</a></li><li><a href="/atc/J05A#J05A">J05A &#8212; DIRECT ACTING ANTIVIRALS</a></li><li><a href="/atc/J05AE#J05AE">J05AE &#8212; Protease inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>08:18.08.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01072.pdf?1265922798">show</a>(412 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01048">Abacavir</a></td><td>The serum concentration of Abacavir may be decreased by protease inhibitors such as Atazanavir. The antiviral response should be closely monitored.</td></tr><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>The protease inhibitor, atazanavir, may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Increased risk of cardiotoxicity and arrhythmias.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>The protease inhibitor, atazanavir, may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Atazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01244">Bepridil</a></td><td>Atazanavir may increase the effect and toxicity of bepridil.</td></tr><tr><td><a href="/drugs/DB01294">Bismuth Subsalicylate</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if atazanavir is initiated, discontinued or dose changed. Dosage adjustments may be required. </td></tr><tr><td><a href="/drugs/DB00921">Buprenorphine</a></td><td>Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects. </td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Atazanavir may increase serum level of clarithromycin.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Atazanavir may increase the therapeutic and adverse effects of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Atazanavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if atazanavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Atazanavir may increase the therapeutic and adverse effects of dihydroergotamine.</td></tr><tr><td><a href="/drugs/DB01341">Dihydroquinidine barbiturate</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01375">Dihydroxyaluminium</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Atazanavir may increase the therapeutic and adverse effects of diltiazem resulting in increased risk of AV block. Consider alternate therapy, a 50% dose reduction of diltiazem and monitor for changes in the therapeutic and adverse effects of diltiazem if atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Decreases metabolism, will increase effect/level of eltrombopag. UDP-glucuronosyltransferase inhibition.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Atazanavir may increase the effect and toxicity of ergotamine.</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00736">Esomeprazole</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Atazanavir, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. 

Etravirine, when administered concomitantly with Atazanavir, may expereince an increase in serum concentrations. 

Recommended to avoid use of this combination.  </td></tr><tr><td><a href="/drugs/DB00927">Famotidine</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Increased risk of hyperbilirubinemia with this association</td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>Increases levels/effect of irinotecan</td></tr><tr><td><a href="/drugs/DB00448">Lansoprazole</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00281">Lidocaine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Atazanavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB01378">Magnesium</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01377">Magnesium oxide</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00653">Magnesium Sulfate</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00353">Methylergometrine</a></td><td>Increases the effect and toxicity of ergot derivative</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Atazanavir may increase the effect and toxicity of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00585">Nizatidine</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>This gastric pH modifier decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>The protease inhibitor, atazanavir, may increase the effect and toxicity of pimozide.</td></tr><tr><td><a href="/drugs/DB08860">Pitavastatin</a></td><td>Increases serum concentration of pitavastatin and the potential for adverse drug reactions. Avoid concomitant drug therapy.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if atazanavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Increased risk of cardiotoxicity and arrhythmias.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir.</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Atazanavir increases levels/toxicity of ramelteon</td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>Ranitidine may decrease the levels/effects of atazanavir.</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Atazanavir may increase levels/toxicity of rifabutin.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin reduces levels and efficacy of atazanavir</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Association with dose adjustment</td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>Increases the effect and toxicity of sildenafil</td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Increases the effect and toxicity of immunosuppressant</td></tr><tr><td><a href="/drugs/DB01390">Sodium bicarbonate</a></td><td>This gastric pH modifier decreases the levels/effect of atazanavir</td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>St. John's Wort decreases the levels/effects of atazanavir</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible increase in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The protease inhibitor, Atazanavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Atazanavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Atazanavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. </td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Atazanvir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Atazanavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Atazanavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00300">Tenofovir</a></td><td>Concomitant therapy may result in decreased serum levels of Atazanavir and increased levels of Tenofovir. Concomitant therapy should only be used with the inclusion of Ritonavir.</td></tr><tr><td><a href="/drugs/DB00906">Tiagabine</a></td><td>The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Atazanavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inhibitor, Atazanavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Atazanavir is initiated, discontinued to dose changed. </td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Atazanavir may increase the effect and toxicity of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. 
</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin.</td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Administration with food reduces pharmacokinetic variability.</li>
<li>Food increases product absorption.</li></ul></td></tr></tbody></table>